Effects of Combined Treatment with Aminoglutethimide and 4-Hydroxyandrostenedione on Breast Cancer
Author Information
Author(s): F.A. MacNeill, S. Jacobs, P.E. L0nning, T.J. Powles, M. Dowsett
Primary Institution: Royal Marsden Hospital
Hypothesis
Does the addition of aminoglutethimide to 4-hydroxyandrostenedione treatment enhance aromatase inhibition and estrogen suppression in post-menopausal women with advanced breast cancer?
Conclusion
The study found that adding aminoglutethimide did not significantly enhance aromatase inhibition but did further suppress plasma oestrone sulphate levels.
Supporting Evidence
- Aromatase inhibition was nearly identical in both treatment situations.
- There was no significant suppression of plasma oestradiol or oestrone levels with the addition of AG.
- Adding AG caused a further suppression of plasma oestrone sulphate compared to 40HA monotherapy.
Takeaway
This study looked at how two drugs work together to lower estrogen levels in women with breast cancer, and found that one drug didn't make the other work better.
Methodology
Ten post-menopausal women with advanced breast cancer were treated with 4-hydroxyandrostenedione followed by aminoglutethimide, measuring aromatase activity and serum estrogen levels.
Limitations
The study had a small sample size and did not evaluate the plasma levels of 4-hydroxyandrostenedione.
Participant Demographics
All participants were post-menopausal women with advanced metastatic breast cancer.
Statistical Information
P-Value
p<0.025
Statistical Significance
p<0.025
Want to read the original?
Access the complete publication on the publisher's website